Article ID Journal Published Year Pages File Type
10914736 Molecular Oncology 2015 9 Pages PDF
Abstract
In this paper, we describe methods and examples of benefit-risk assessment of targeted drugs, recent initiatives from EMA and FDA on improving communication about benefits and risks, and discuss future steps.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Assessment of benefits and risks in development of targeted therapies for cancer - The view of regulatory authorities
Authors
, , , ,